Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Revenue (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Revenue for 6 consecutive years, with $380000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 174.8% year-over-year to $380000.0, compared with a TTM value of $243.9 million through Dec 2025, up 293912.05%, and an annual FY2025 reading of $243.9 million, changed N/A over the prior year.
  • Revenue was $380000.0 for Q4 2025 at Keros Therapeutics, down from $14.1 million in the prior quarter.
  • Across five years, Revenue topped out at $211.2 million in Q1 2025 and bottomed at -$18.0 million in Q2 2022.
  • Average Revenue over 5 years is $18.7 million, with a median of $261500.0 recorded in 2023.
  • Peak annual rise in Revenue hit 1800100.0% in 2022, while the deepest fall reached 18100.0% in 2022.
  • Year by year, Revenue stood at $17.9 million in 2021, then crashed by 200.56% to -$18.0 million in 2022, then surged by 100.79% to $143000.0 in 2023, then tumbled by 455.24% to -$508000.0 in 2024, then surged by 174.8% to $380000.0 in 2025.
  • Business Quant data shows Revenue for KROS at $380000.0 in Q4 2025, $14.1 million in Q3 2025, and $18.2 million in Q2 2025.